Suven Life Sciences sparkles on patient
DSIJ Intelligence / 30 Jan 2017
Suven Life Sciences (Suven) has grabbed a patent from USA, corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
Suven Life Sciences (Suven) has grabbed a patent from USA, corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
The patent is valid till 2034, and with the addition of this new patent, the company now has a total of 25 granted patents from USA.
Suven's granted patents are exclusive intellectual property and are achieved through the internal discovery research efforts. The company's inventions are licensed at various phases of clinical development like in Phase-I or Phase-II.
On the financial front, Suven's revenue declined 1.18 per cent to Rs 116 crore in Q2FY17 as compared to the same period in previous financial year. The company's EBITDA too rose by 18.17 per cent to Rs 36.88 crore in Q2FY17 on yearly basis. Its net profit also increased 5.23 per cent to Rs 26.56 crore in Q2FY17 as compared to the same period in previous fiscal year.
The share price of Suven increased 4.22 per cent on bourses in early trades and is trading at Rs 178.85 in an intraday basis.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.